drugset / Trial / NCT03272256
Phase 1 Study of IM156 in Patients With Advanced Solid Tumor and Lymphoma
NaSequentialOpen-labelTreatment
Summary
The main purpose of first-in-human IM156 study is to evaluate the safety and tolerability, and to determine the maximum tolerated dose and recommended phase 2 dose of IM156.
Timeline
- Start
- 2017-10-09
- Primary completion
- 2019-12-02
- Completion
- 2020-07-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LIXUMISTAT | Small molecule | — | — |